Risk Factors for Osteoporosis among Patients with Inflammatory Bowel Disease-Do We Already Know Everything?
inflammatory bowel diseases
metabolic bone disease
osteoporosis
physical activity
vitamin D
Journal
Nutrients
ISSN: 2072-6643
Titre abrégé: Nutrients
Pays: Switzerland
ID NLM: 101521595
Informations de publication
Date de publication:
24 Feb 2023
24 Feb 2023
Historique:
received:
27
01
2023
revised:
21
02
2023
accepted:
23
02
2023
entrez:
11
3
2023
pubmed:
12
3
2023
medline:
15
3
2023
Statut:
epublish
Résumé
There are many known risk factors for osteoporosis (OST) among patients with inflammatory bowel disease (IBD), one of which is physical activity. The aim of the study is to assess the frequency and risk factors of OST among 232 patients with IBD compared to a group of 199 patients without IBD. The participants underwent dual-energy X-ray absorptiometry, laboratory tests, and completed a questionnaire about their physical activity. It was found that 7.3% of IBD patients suffered from OST. Male gender, ulcerative colitis, extensive inflammation in the intestine, exacerbation of disease, rare physical activity, other forms of physical activity, past fractures, lower levels of osteocalcin, and higher levels of C-terminal telopeptide of type 1 collagen were risk factors for OST. As many as 70.6% of OST patients were rarely physically active. OST is a common problem in IBD patients. OST risk factors differ significantly between the general population and those with IBD. Modifiable factors can be influenced by patients and by physicians. The key to OST prophylaxis may be regular physical activity, which should be recommended in clinical remission. It may also prove valuable to use markers of bone turnover in diagnostics, which may enable decisions regarding therapy.
Identifiants
pubmed: 36904150
pii: nu15051151
doi: 10.3390/nu15051151
pmc: PMC10005035
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
World Health Organ Tech Rep Ser. 2003;921:1-164, back cover
pubmed: 15293701
Appl Health Econ Health Policy. 2013 Oct;11(5):485-97
pubmed: 23868102
Endocr Pract. 2020 May;26(Suppl 1):1-46
pubmed: 32427503
Scand J Gastroenterol. 2001 Jul;36(7):759-65
pubmed: 11444476
Pol Arch Intern Med. 2022 May 30;132(5):
pubmed: 35044144
J Intern Med. 2000 Jan;247(1):63-70
pubmed: 10672132
World J Gastrointest Pathophysiol. 2015 Nov 15;6(4):210-8
pubmed: 26600979
Gut. 2000 Feb;46(2):176-81
pubmed: 10644310
World J Gastroenterol. 2020 Sep 21;26(35):5362-5374
pubmed: 32994694
Calcif Tissue Int. 2019 Mar;104(3):235-238
pubmed: 30796490
J Bone Miner Metab. 2009;27(4):456-63
pubmed: 19333683
Aliment Pharmacol Ther. 2001 Jun;15(6):783-92
pubmed: 11380316
Eur J Gastroenterol Hepatol. 2003 Dec;15(12):1267-73
pubmed: 14624148
Nutrients. 2021 May 30;13(6):
pubmed: 34070791
Am J Gastroenterol. 1998 May;93(5):848-9
pubmed: 9625151
Pol Arch Intern Med. 2022 Dec 21;132(12):
pubmed: 36026616
Medicine (Baltimore). 2017 Jun;96(22):e6788
pubmed: 28562531
Scand J Gastroenterol. 2021 Jun;56(6):699-707
pubmed: 33945377
Gynecol Endocrinol. 2020 Apr;36(4):285-288
pubmed: 31711322
Gut. 1997 Mar;40(3):313-9
pubmed: 9135518
Prz Gastroenterol. 2021;16(4):257-296
pubmed: 34976235
Med Clin (Barc). 2011 Jun 11;137(2):62-5
pubmed: 21185038
Eur J Gastroenterol Hepatol. 2009 Feb;21(2):159-66
pubmed: 19098682
Gut. 1977 Mar;18(3):171-5
pubmed: 856674
Bone. 2007 Jun;40(6):1610-4
pubmed: 17433801
Curr Opin Gastroenterol. 2018 Jul;34(4):217-225
pubmed: 29762159
Gut. 2004 Aug;53(8):1129-36
pubmed: 15247180
J Clin Med. 2022 Jul 16;11(14):
pubmed: 35887903
Am J Gastroenterol. 2008 Jun;103(6):1451-9
pubmed: 18422819
Am J Epidemiol. 2002 Jul 1;156(1):1-10
pubmed: 12076883